DCM
RPTX

Difesa Capital Management’s Repare Therapeutics RPTX Stock Holding History

Difesa Capital Management’s Portfolio RPTX Stock Details RPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-15,416
Closed -$163K – 23
2023
Q2 		$163K Hold
15,416
– – 0.43% 24
2023
Q1 		$152K Hold
15,416
– – 0.1% 74
2022
Q4 		$227K Hold
15,416
– – 0.18% 81
2022
Q3 		$187K Buy
+15,416
New +$198K 0.1% 97

Other funds holding RPTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Difesa Capital Management's RPTX Position: Q3 2023 in Review

Difesa Capital Management sold out of Repare Therapeutics (RPTX) in Q3 2023, closing a stake of 15,416 shares — an estimated $163K sold.

Difesa Capital Management first reported a position in RPTX in Q3 2022 and held it in 4 quarters. The position peaked at $227K in Q4 2022. 76 funds tracked by Wall St. Rank hold RPTX as of Q3 2023.

  • Difesa Capital Management reported no remaining Repare Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Difesa Capital Management sold 15,416 Repare Therapeutics shares in Q3 2023, an estimated $163K.
  • Difesa Capital Management first reported a position in Repare Therapeutics in Q3 2022 and held it in 4 quarters.
  • Difesa Capital Management's Repare Therapeutics position peaked at $227K in Q4 2022.
  • 76 funds tracked by Wall St. Rank held Repare Therapeutics as of Q3 2023.

Based on Difesa Capital Management's 13F filing for Q3 2023.